Genmab increases income in Q3 and maintains upgraded full-year guidance
Genmab, which recently upgraded its 2021 financial guidance, ended the third quarter with significant progress on both the top and bottom lines compared to the same period last year.
by andreas lønstrup, translated by catherine brett
During Q3 2021, Genmab generated a revenue of DKK 2310m (USD 357m) compared to DKK 1724m (USD 266m) for the same period last year. Net incomes totaled DKK 890m (USD 173.4m) in the third quarter of 2021, compared to DKK 530m (USD 81.8m) in the same period of 2020.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab upgrades financial guidance again
For subscribers
Lundbeck ready to take Genmab antibody to phase II
For subscribers
.jpg&w=384&q=75)
